- Home
- HSTM vs GERN Comparison
HSTM vs GERN Comparison
Compare HSTM & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSTM
- GERN
- Stock Information
- Founded
- HSTM 1990
- GERN 1990
- Country
- HSTM United States
- GERN United States
- Employees
- HSTM N/A
- GERN N/A
- Industry
- HSTM Computer Software: Programming Data Processing
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- HSTM Technology
- GERN Health Care
- Exchange
- HSTM Nasdaq
- GERN Nasdaq
- Market Cap
- HSTM 828.5M
- GERN 823.0M
- IPO Year
- HSTM 2000
- GERN 1996
- Fundamental
- Price
- HSTM $29.01
- GERN $1.28
- Analyst Decision
- HSTM Hold
- GERN Buy
- Analyst Count
- HSTM 2
- GERN 8
- Target Price
- HSTM $28.00
- GERN $3.71
- AVG Volume (30 Days)
- HSTM 197.2K
- GERN 6.4M
- Earning Date
- HSTM 10-20-2025
- GERN 11-06-2025
- Dividend Yield
- HSTM 0.43%
- GERN N/A
- EPS Growth
- HSTM 14.03
- GERN N/A
- EPS
- HSTM 0.67
- GERN N/A
- Revenue
- HSTM $295,211,000.00
- GERN $164,447,000.00
- Revenue This Year
- HSTM $4.90
- GERN $175.15
- Revenue Next Year
- HSTM $5.12
- GERN $56.61
- P/E Ratio
- HSTM $43.14
- GERN N/A
- Revenue Growth
- HSTM 3.50
- GERN 11877.20
- 52 Week Low
- HSTM $25.36
- GERN $1.09
- 52 Week High
- HSTM $34.24
- GERN $4.83
- Technical
- Relative Strength Index (RSI)
- HSTM 65.53
- GERN 41.89
- Support Level
- HSTM $27.33
- GERN $1.27
- Resistance Level
- HSTM $29.44
- GERN $1.33
- Average True Range (ATR)
- HSTM 0.50
- GERN 0.06
- MACD
- HSTM 0.09
- GERN -0.02
- Stochastic Oscillator
- HSTM 79.38
- GERN 7.69
About HSTM HealthStream Inc.
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.